ELAC2 Polymorphisms and Prostate Cancer Risk: a Meta-analysis Based on 18 Case-control Studies

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2010 Mar 17

PMID 20231859

Citations 19

Authors

B Xu

N Tong

J-M Li

Z-D Zhang

H-F Wu

Affiliations

Soon will be listed here.

Abstract

Polymorphisms in the elaC homolog-2 (ELAC2)/HPC2 gene have been hypothesized to alter the risk of prostate cancer. However, the results of the related published studies remained conflicting. We performed a meta-analysis of 18 studies evaluating the association between ELAC2 Ser217Leu and Ala541Thr polymorphisms and prostate cancer risk. Overall, ELAC2 Leu217 allele was associated with increased prostate cancer risk as compared with the Ser217 allele (odds ratio (OR)=1.13, 95% confidence interval (CI): 1.03-1.24, P=0.019 for heterogeneity), as well as in the heterozygote comparison (OR=1.21, 95% CI: 1.07-1.36, P=0.034 for heterogeneity) and the dominant genetic model (OR=1.20, 95% CI: 1.07-1.35, P=0.025 for heterogeneity). Furthermore, the ELAC2 Thr541 allele was associated with increased prostate cancer risk as compared with the Ala541 allele (OR=1.22, 95% CI: 1.00-0.48, P=0.131 for heterogeneity). In the stratified analyses for Ser217Leu polymorphism, there was significantly increased prostate cancer risk in Asian and Caucasian populations, and studies using sporadic and familial prostate cancer cases. Similar result was found in the Asian population in the stratified analyses for Ala541Thr polymorphism. This meta-analysis showed evidence that ELAC2 Ser217Leu and Ala541Thr polymorphisms were associated with prostate cancer risk, and might be low-penetrance susceptibility markers of prostate cancer.

Citing Articles

Structural insights into human ELAC2 as a tRNA 3' processing enzyme.

Xue C, Tian J, Chen Y, Liu Z Nucleic Acids Res. 2024; 52(21):13434-13446.

PMID: 39494506 PMC: 11602120. DOI: 10.1093/nar/gkae1014.

Transfer RNAs as dynamic and critical regulators of cancer progression.

Pinzaru A, Tavazoie S Nat Rev Cancer. 2023; 23(11):746-761.

PMID: 37814109 DOI: 10.1038/s41568-023-00611-4.

Multi-omic profiling reveals an RNA processing rheostat that predisposes to prostate cancer.

Stentenbach M, Ermer J, Rudler D, Perks K, Raven S, Lee R EMBO Mol Med. 2023; 15(6):e17463.

PMID: 37093546 PMC: 10245041. DOI: 10.15252/emmm.202317463.

Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso.

Traore A, Ky B, Traore L, Zohoncon T, Zoure A, Yonli A Prostate Cancer. 2023; 2022:3610089.

PMID: 36643816 PMC: 9833931. DOI: 10.1155/2022/3610089.

Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches.

Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S Molecules. 2022; 27(17).

PMID: 36080493 PMC: 9457814. DOI: 10.3390/molecules27175730.

References

Vesprini D, Nam R, Trachtenberg J, Jewett M, Tavtigian S, Emami M . HPC2 variants and screen-detected prostate cancer. Am J Hum Genet. 2001; 68(4):912-7. PMC: 1275645. DOI: 10.1086/319502. View

Meitz J, Edwards S, Easton D, Murkin A, Ardern-Jones A, Jackson R . HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. Br J Cancer. 2002; 87(8):905-8. PMC: 2376179. DOI: 10.1038/sj.bjc.6600564. View

Zhuang W, Wu X, Zhou Y, Liu L, Liu G, Wu T . Interleukin10 -592 promoter polymorphism associated with gastric cancer among Asians: a meta-analysis of epidemiologic studies. Dig Dis Sci. 2009; 55(6):1525-32. DOI: 10.1007/s10620-009-0922-1. View

Noonan-Wheeler F, Wu W, Roehl K, Klim A, Haugen J, Suarez B . Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate. 2005; 66(1):49-56. DOI: 10.1002/pros.20320. View

Imamoto T, Suzuki H, Utsumi T, Endo T, Takano M, Yano M . Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. Future Oncol. 2009; 5(7):1005-13. DOI: 10.2217/fon.09.82. View

Rennert H, Zeigler-Johnson C, Addya K, Finley M, Walker A, Spangler E . Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev. 2005; 14(4):949-57. DOI: 10.1158/1055-9965.EPI-04-0637. View

Carter B, Beaty T, Steinberg G, Childs B, Walsh P . Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A. 1992; 89(8):3367-71. PMC: 48868. DOI: 10.1073/pnas.89.8.3367. View

Khan N, Afaq F, Mukhtar H . Lifestyle as risk factor for cancer: Evidence from human studies. Cancer Lett. 2010; 293(2):133-43. PMC: 2991099. DOI: 10.1016/j.canlet.2009.12.013. View

Quinn M, Babb P . Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int. 2002; 90(2):174-84. DOI: 10.1046/j.1464-410x.2002.02823.x. View

10.

Robbins C, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T . Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate. 2008; 68(16):1790-7. PMC: 4097307. DOI: 10.1002/pros.20841. View

11.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

12.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

13.

Fujiwara H, Emi M, Nagai H, Nishimura T, Konishi N, Kubota Y . Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series. J Hum Genet. 2003; 47(12):641-8. DOI: 10.1007/s100380200099. View

14.

Takahashi H, Lu W, Watanabe M, Katoh T, Furusato M, Tsukino H . Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men. Int J Cancer. 2003; 107(2):224-8. DOI: 10.1002/ijc.11347. View

15.

Rebbeck T, Walker A, Zeigler-Johnson C, Weisburg S, Martin A, Nathanson K . Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet. 2000; 67(4):1014-9. PMC: 1287872. DOI: 10.1086/303096. View

16.

Stanford J, Sabacan L, Noonan E, Iwasaki L, Shu J, Feng Z . Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study. Cancer Epidemiol Biomarkers Prev. 2003; 12(9):876-81. View

17.

Adler D, Kanji N, Trpkov K, Fick G, Hughes R . HPC2/ELAC2 gene variants associated with incident prostate cancer. J Hum Genet. 2003; 48(12):634-638. DOI: 10.1007/s10038-003-0091-6. View

18.

Yokomizo A, Koga H, Kinukawa N, Tsukamoto T, Hirao Y, Akaza H . HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. Prostate. 2004; 61(3):248-52. DOI: 10.1002/pros.20107. View

19.

Shea P, Ferrell R, Patrick A, Kuller L, Bunker C . ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago. Hum Genet. 2002; 111(4-5):398-400. DOI: 10.1007/s00439-002-0816-1. View

20.

Dickersin K, Min Y, Meinert C . Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992; 267(3):374-8. View